cas12281-sup-0001-FigureS1.epsimage/eps1472KFig. S1. Immunoblotting analysis of poly (ADP-ribose) PAR and poly (ADP-ribose) polymerase 1 (PARP1) in esophageal squamous cell carcinoma TE11 cells after exposure to 3-aminobenzamide (3-AB).
cas12281-sup-0002-FigureS2.epsimage/eps2079KFig. S2. Treatment of poly (ADP-ribose) polymerase 1 (PARP1)-depleted esophageal squamous cell carcinoma TE11 cells with anticancer drugs.
cas12281-sup-0003-FigureS3.epsimage/eps1266KFig. S3. Numbers of γH2AX and RAD51 foci per nucleus after treatment with anticancer drugs.
cas12281-sup-0004-FigureS4.epsimage/eps631KFig. S4. Time schedule of treatments with anticancer drugs.
cas12281-sup-0005-FigureS5.epsimage/eps1488KFig. S5. Dose–response analysis of the survival of esophageal squamous cell carcinoma TE11 cells treated with cisplatin and 3-aminobenzamide (3-AB) in combination.
cas12281-sup-0006-FigureS6.epsimage/eps1635KFig. S6. Knockdown of RAD51 protein using RAD51 siRNA (#2) also renders TE11 cells hypersensitive to combinations of cisplatin and either 3-aminobenzamide (3-AB) or 5-fluorouracil (5-FU).
cas12281-sup-0007-DataS1.docWord document49KData S1. Supplementary experimental procedures and discussion.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.